Gait disturbance and lower limb pain in a patient with PIK3CA-related disorder.

[1]  R. Hennekam,et al.  Correspondence to Gripp et al. nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation , 2017, American journal of medical genetics. Part A.

[2]  R. Touraine,et al.  Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing , 2017, Genetics in Medicine.

[3]  J. Martinez-Agosto,et al.  Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies , 2016, American journal of medical genetics. Part C, Seminars in medical genetics.

[4]  M. Scavina,et al.  Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation , 2016, American journal of medical genetics. Part A.

[5]  J. Shendure,et al.  PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution , 2016, JCI insight.

[6]  J. Rhie,et al.  Intramuscular Lipoma-Induced Occipital Neuralgia on the Lesser Occipital Nerve. , 2016, The Journal of craniofacial surgery.

[7]  V. Parker,et al.  Somatic mosaicism of the PIK3CA gene identified in a Hungarian girl with macrodactyly and syndactyly. , 2016, European journal of medical genetics.

[8]  K. Anderson,et al.  Somatic PIK3CA mutations as a driver of sporadic venous malformations , 2016, Science Translational Medicine.

[9]  J. Uitto,et al.  Klippel–Trenaunay syndrome belongs to the PIK3CA‐related overgrowth spectrum (PROS) , 2016, Experimental dermatology.

[10]  M. Cutrone,et al.  Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors , 2015, PloS one.

[11]  Julie C. Sapp,et al.  PIK3CA‐related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation , 2015, American journal of medical genetics. Part A.

[12]  Julie C. Sapp,et al.  Clinical Delineation and Natural History of the PIK3CA-Related Overgrowth Spectrum** , 2014, American journal of medical genetics. Part A.

[13]  Ugur M Ayturk,et al.  Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. , 2012, American journal of human genetics.

[14]  Ninib Baryawno,et al.  Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo , 2011, International journal of cancer.

[15]  V. Sutton,et al.  Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation , 2011, Pediatric blood & cancer.

[16]  D. Gutknecht.  Painful Intramuscular Lipoma of the Thigh , 2004, Southern medical journal.

[17]  Kun-Liang Guan,et al.  Dysregulation of the TSC-mTOR pathway in human disease , 2004, Nature Genetics.